Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Niagen Bioscience selected Evotec as a contract research organization to advance preclinical development for NB4168, its lead oral small-molecule candidate for the rare pediatric disease Ataxia Telangiectasia. Evotec will conduct pharmacokinetic, pharmacodynamic, and bioanalytical studies at its Verona, Italy campus, utilizing its INDiGO platform to support IND-enabling activities and streamline the path to the clinic.
Key figures
- Drug Name
- NB4168
- Target disease
- Ataxia Telangiectasia (A-T)
- Incidence rate us
- 1 in 40,000
- Designation status
- FDA Rare Pediatric Disease, EMA Orphan Medicinal Product
- Incidence rate europe
- 1 in 150,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.